CollPlant And Stratasys Begin Pre-Clinical Study Of 3D-Printed 200cc Regenerative Breast Implants Using CollPlant's rhCollagen-Based Bioinks On Stratasys' Origin Printer
Portfolio Pulse from Benzinga Newsdesk
CollPlant and Stratasys have initiated a pre-clinical study for 3D-printed regenerative breast implants using CollPlant's rhCollagen-based bioinks on Stratasys' Origin printer. This project targets a $3 billion market opportunity.
August 19, 2024 | 12:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Stratasys is collaborating with CollPlant on a pre-clinical study for 3D-printed regenerative breast implants, using its Origin printer. This venture targets a significant $3 billion market opportunity.
The collaboration with CollPlant on a potentially groundbreaking product in a large market could enhance Stratasys' reputation and market position in the 3D printing and medical sectors, likely boosting investor sentiment.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80